Hiromu Horitani

1PUBLICATIONS
2CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (1)

|Jul 20, 2026
Short-term efficacy and safety of enfortumab vedotin plus pembrolizumab as a first-line treatment for advanced urothelial carcinoma regardless of cisplatin eligibility.

Pageof 1

Frequent Collaborators

1 joint publications

Takuji Hayashi

1 joint publications

Atsunari Kawashima